Repare Therapeutics Inc. (NASDAQ:RPTX) Stake Increased by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 20.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,000 shares of the company’s stock after acquiring an additional 4,000 shares during the period. Vontobel Holding Ltd. owned 0.06% of Repare Therapeutics worth $83,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in shares of Repare Therapeutics in the 2nd quarter valued at about $110,000. Exchange Traded Concepts LLC increased its holdings in Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after buying an additional 8,809 shares during the last quarter. Marshall Wace LLP acquired a new stake in Repare Therapeutics during the second quarter valued at approximately $273,000. Opaleye Management Inc. bought a new position in Repare Therapeutics during the 1st quarter worth approximately $318,000. Finally, Bank of Montreal Can grew its position in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock worth $366,000 after acquiring an additional 5,673 shares in the last quarter. 85.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on RPTX shares. Lifesci Capital raised Repare Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Repare Therapeutics in a research note on Monday, September 23rd.

Repare Therapeutics Stock Down 2.6 %

Shares of NASDAQ RPTX opened at $3.43 on Thursday. The firm’s 50-day moving average price is $3.21 and its two-hundred day moving average price is $3.39. Repare Therapeutics Inc. has a 52-week low of $2.71 and a 52-week high of $8.49. The stock has a market capitalization of $145.60 million, a P/E ratio of -2.09 and a beta of 0.72.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.03. The business had revenue of $1.07 million for the quarter, compared to the consensus estimate of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. As a group, equities research analysts expect that Repare Therapeutics Inc. will post -2.15 earnings per share for the current year.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.